Subscribe to Search results

Blood transfusion services were required to ask about family history of CJD.

Published on:

The Chief Medical Officer issued a statement reporting that three patients who had suffered from vCJD had been blood donors, and a fourth was suspected of having been one too.

Published on:

The Advisory Committee on the Microbiological Safety of Blood and Tissues for Transplantation agreed that recipients of vCJD-implicated product should not be informed.

Published on:

The National Blood Authority initiated a recall of plasma products after establishing that they contained contributions from a donor who subsequently developed vCJD.

Published on:

The National Blood Authority began working towards the possible extension of leucodepletion of blood.

Published on:

The United Kingdom Haemophilia Centre Directors' Organisation recommended recombinant Factor 8 for Haemophilia A.

Published on:

The Government announced the leucodepletion programme, which was implemented by the National Blood Service over time and completed by October 1999.

Published on:

The Government announced a programme to phase out the use of UK-sourced plasma in the manufacture of blood products.

Published on:

The CJD Incidents Panel was established.

Published on:

The BSE Inquiry published its report.

Published on:

The Government announced financial support packages for victims of vCJD.

Published on:

The Department of Health purchased the largest remaining independent US plasma collector, Life Resources Incorporated, to ensure the continuity of supply without needing to rely on UK-sourced plasma.

Published on:

The death of a patient thought to have been infected with vCJD through transfusion was announced. 15 individuals who received donations of blood from donors who subsequently developed vCJD were to be notified by the Health Protection Agency.

Published on:

The Government announced the exclusion of blood donors who had received transfusions of whole blood components since January 1980.

Published on:

The second case of transfusion-related vCJD was reported.

Published on:

People with a bleeding disorder who were treated with UK-sourced pooled factor concentrates or antithrombin between 1980 and 2001 were considered at risk of vCJD and informed by their haemophilia centre.

Published on:

WHO identified record keeping as key to reducing the risks of hepatitis.

Published on:

Guidance and circulars were issued containing advice as to the retention and disposal of medical records.

Published on:

The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody was opposed to the "routine determination of transaminase levels" but considered further investigation to be warranted and deferred further discussions to its next meeting when Dr Cleghorn would be in attendance.

Published on:

The Advisory Group on testing of the presence of Hepatitis B surface antigen and its antibody's terms of reference included "To advise the Department on measures which should be introduced to offer greater safety to recipients of blood and blood products and to protect the interests of blood donors."

Published on: